Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment.Mini reviews in medicinal chemistry · 2018
   Review
2. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.Oncotarget · 2015
   Article
3. Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Cell cycle (Georgetown, Tex.) · 2014
   Article
4. Immunosuppressants in cancer prevention and therapy.Oncoimmunology · 2013
   Review
5. Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab.Cell cycle (Georgetown, Tex.) · 2013
   Article
6. Inhibitory effects ofExperimental and therapeutic medicine · 2013
   Article
7. Recent discoveries in the cycling, growing and aging of the p53 field.Aging · 2012
   Review
8. Rapalogs in cancer prevention: anti-aging or anticancer?Cancer biology & therapy · 2012
   Review
9. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Oncotarget · 2012
   Review
10. NRF2 and p53: Januses in cancer?Oncotarget · 2012
    Review
11. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.Oncotarget · 2012
    Article
12. Cyclotherapy: opening a therapeutic window in cancer treatment.Oncotarget · 2012
    Article
13. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.Cell cycle (Georgetown, Tex.) · 2012
    Article
14. Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment.Oncotarget · 2012
    Review
15. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.Cell cycle (Georgetown, Tex.) · 2011
    Article
16. WWP2 ubiquitin ligase and its isoforms: new biological insight and promising disease targets.Cell cycle (Georgetown, Tex.) · 2011
    Article

Corrections and comments

• Comment on
  Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.2011

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as